#EMAS2019 in the news

#EMAS2019 in the news Integrating novel scientific insights into clinical application the multidisciplinary international congress was extremely successful and enjoyed by all participants. As part of its menopause week, the BBC filmed speakers on both women’s and men’s health. The clips are below. We look forward to May 2021 when the next congress will be in…

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

Amsterdam, June 06, 2017 – A new position statement by the European Menopause and Andropause Society(EMAS) published in the journal Maturitas summarises the evidence about drug holidays from bisphosphonates and denosumab in women with postmenopausal osteoporosis. Osteoporosis affects 1 in 3 women. Bisphosphonates, such as alendronate, risendronate and zoledronic acid, and denosumab are used extensively…